Introduction:
Aniphospholipid Syndrome also known as sticky blood or Hughes' syndrome, is an auto immune disease that can cause abnormal blood clotting in any blood vessels-both arteries & veins. As a result it can cause many different problems. These includes clots in the legs known as DVT, miscarriage & dangerous arterial thrombosis resulting in stroke & Heart attacks. Aniphospholipid Syndrome accounts for about one in five DVT & may be to blame in some cases of economy class syndrome, leading to the death of young people traveling on long flight, one in five case of stroke in young people (<45 years) is associated with the condition. APS also accounts for as many as one in five case of miscarriage. Miscarriage is thought to result from disruption of blood flow through small blood vessels of the placenta. The Syndrome has also been linked to pre-eclampsia, placental abruption & intra uterine growth restriction. People with APS are at great risk of -Venus thrombosis in the leg (DVT), arms & internal organ ( kidney, liver, lungs, brain, eye). Arterial thrombosis -which can be lead to recurrent stroke, TIA & Heart attack. Mild thrombocytopenia. Headache-which may be diagnosed as Treatment was started with SC LMW heparin with warfarin. During her whole clinical course, the Pt. did not experience any respiratory or chest symptom such dyspnoea, tachypnoea, chest pain or tachycardia. so pulmonary embolism was not evaluated. The Pt. was suggested to take warfarin indefinitely & to avoid standing & sitting for a long time.
Discussion:
Antiphospholipid syndrome (APS) or otherwise known as Hughes' Syndrome is a disorder which manifests itself by recurrent arterial or venous thrombosis, with persistently elevated levels of antibodies directed against membrane anionic phospholipids (e.g. anti-cardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.
The diagnosis of a definite APS is made by referring to the revised Sapporo Criteria 2006, whereby it consists of at least one clinical criteria, which involves one or more episodes of vascular thrombosis and also one laboratory criteria with positive anticardiolipin (aCL), anti-beta-2 glycoprotein I, or lupus anticoagulant antibody on at least 2 occasions at least 12 weeks apart. The episode of vascular thrombosis must be confirmed by imaging, doppler studies, or histopathology.
This patient fits the clinical diagnosis of antiphospholipid syndrome in view of he presented with two proven episodes of recurrent venous thrombosis,the first one involving the lower limb deep vein thrombosis in 2003, and the second one is the current problem which involved thrombosis of the Rt popliteal vein & a positive antiphospholipid antibody IgG > 100.
The antiphospholipid antibodies associated with APS are anticardiolipin antibodies (aCL), lupus antico-agulants (LAs) which are immunoglobulins directed against plasma proteins (prothrombin or annexin V) and anti-beta-2 glycoprotein-I (anti-beta-2GPI)antibodies. According to a few studies, the prevalence of anti-beta-2 glycoproteins in APLS ranges from zero percent to 90 percent. Anti-beta-2 glycoprotein-I antibodies have higher specificity than aCL for thrombosis.
There were two evaluations conducted of the proposed and revised Sapporo criteria. In the first evaluation by Kaul This patient is likely to have APLS in view of the recurrent venous thrombosis & the laboratory criteria of positive Antiphospholipid IgG >100. There was also no history of trauma and we have ruled out other possibilities like hypercoagulable state and thrombophilia, which can also cause recurrent thrombosis.
Another issue in this patient is whether the APLS is primary or secondary. Primary antiphospholipid syndrome means that the APLS occurs by itself and not associated with a connective tissue disease, particularly with the spectrum of systemic lupus erythematosus. In this patient, he has primary antiphospholipid syndrome in view of negative connective tissue disease screening, namely anti-nuclear antibody (ANA), Anti dsDNA ,complement level C3/C4, rheumatoid factor. There are also no other signs or symptoms suggestive of a related connective tissue disease in the patient. In the European Multicenter Study of 114 patients comparing primary APLS with secondary disease, the two groups were found to have similar clinical and laboratory manifestations of APS.
The patient is treated with lifelong warfarin, with a target INR of 2.0 to 3.0. Anticoagulation is the mainstay treatment for antiphospholipid syndrome. Based on a few studies, the optimum target INR is at a conventional range of 2.0 to 3.0.6 In patients with recurrent thrombosis despite conventional doses of warfarin, the target INR will be higher at 3.0-4.0 based on expert recommendations, and the effect of adding aspirin to warfarin may increase the frequency of bleeding. However, there is no randomized controlled trial to point towards the effectiveness of increasing INR in recurrent thrombosis. The duration of anticoagulation is also another issue. The optimum duration of anticoagulation after the first event of venous thromboembolism is debatable. It has been shown that the presence of anticardiolipin antibodies at the end of six months of treatment was associated with a doubling of the risk of recurrent thrombosis (29 versus 14 percent).Another study has shown that patients with venous hromboembolic episode and antiphospholipid antibodies have an extremely high risk for recurrent venous thrombosis after withdrawal of treatment with oral anticoagulants.Therefore, based on these recommendations, lifelong anticoagulation is the preferred choice.
